Compositions and methods for the treatment of metabolic disorders

A compound of the general formula:

• wherein R1 is hydrogen, methyl, ethyl, or propyl;
• R2, and R3 are the same or different and are selected from the group consisting of:
• a1) hydrogen;
• a) hydroxy;
• b) substituted or unsubstituted C1-10 alkyl;
• c) substituted or unsubstituted C2-10 alkenyl;
• d) substituted or unsubstituted C2-10 alkynyl;
• e) substituted or unsubstituted C3-6 cycloalkyl;
• f) substituted or unsubstituted aryl;
• g) substituted or unsubstituted heteroaryl;
• wherein said substitutions in b), c), d), e), f), and/or g) are optionally further substituted with 1-5 groups selected from the group consisting of:
• 1) hydroxy;
• 2) —(C═O)Ra;
• 3) —(C═O)ORa;
• 4) —(C═O)H;
• 5) —(C═O)OH;
• 6) —O(CH2)nCOORa, wherein n=1-10;
• 7) halo;
• 8) cyano;
• 9) carboxy;
• 10) amino;
• 11) mono-substituted amino;
• 12) di-substituted amino;
• 13) amido;
• 14) mono-substituted amido;
• 15) di-substituted amido;
• and
• 16) any combination thereof,
• wherein in 2), 3), or 6) Ra is a C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-6 cycloalkyl, aryl, or heteroaryl;
• h) —(C═O)Ra;
• i) —(C═O)ORa;
• j) —(C═O)H;
• k) —(C═O)OH;
• l) —O(CH2)nCOORa, wherein n=1-10,
• wherein in h), i), or 1), Ra is a C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-6 cycloalkyl, aryl or heteroaryl;
• m) halo;
• n) cyano;
• o) carboxy;
• p) amino;
• q) mono-substituted amino;
• r) di-substituted amino,
• s) amido;
• t) mono-substituted amido;
• and
• u) di-substituted amido;
• wherein one or more of said mono-substituted amino, di-substituted amino, mono-substituted amido, and di-substituted amido have a substitution selected from the group consisting of C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-6 cycloalkyl, aryl, heteroaryl, sulfoxide, sulfone, sulfonate, alkyl sulfonate, sulfonic acid, and any combination thereof,
• wherein in u) said alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heteroaryl are optionally further substituted with 1-5 groups selected from the group consisting of:
• i) hydroxy;
• ii) —(C═O)Ra;
• iii) —(C═O)ORa;
• iv) —(C═O)H;
• v) —(C═O)OH;
• vi) —O(CH2)nCOORa, wherein n=1-10,
• wherein in ii), iii), or vi) Ra is a C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-6 cycloalkyl, aryl or heteroaryl;
• vii) halo;
• viii) cyano;
• ix) carboxy;
• x) amino;
• xi) mono-substituted amino;
• xii) di-substituted amino;
• xiii) amido;
• xiv) mono-substituted amido;
• xv) di-substituted amido;
• and
• xvi) any combination thereof;
• Y1 is nitrogen, Y2 and Y3 are the same or different and are sulfur or —CH═;
• R4 is mono-substituted amino or di-substituted amino wherein said mono-substituted amino and di-substituted amino have a substitution independently selected from the group consisting of C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-6 cycloalkyl, aryl, heteroaryl, sulfoxide, sulfone, sulfonate, alkyl sulfonate, sulfonic acid, and any combination thereof,
• wherein in u), said alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heteroaryl are optionally further substituted with 1-5 groups selected from the group consisting of:
• i) hydroxy;
• ii) —(C═O)Ra;
• iii) —(C═O)ORa;
• iv) —(C═O)H;
• v) —(C═O)OH;
• vi) —O(CH2)nCOORa, wherein n=1-10,
• wherein in ii), iii), or vi) Ra is a C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-6 cycloalkyl, aryl or heteroaryl;
• vii) halo;
• viii) cyano;
• ix) carboxy;
• x) amino;
• xi) mono-substituted amino;
• xii) di-substituted amino;
• xiii) amido;
• xiv) mono-substituted amido;
• xv) di-substituted amido;
• and
• xvi) any combination thereof;
• or a pharmaceutically acceptable salt thereof.